Profound(US:PROF)2026-03-05 22:32Financial Data and Key Metrics Changes - For Q4 2025, the company recorded revenue of $6 million, a 43% increase from CAD 4.2 million in the same period last year [4][5] - Gross margin in Q4 2025 was 67%, down from 71% in Q4 2024, primarily due to product mix and introductory pricing in new markets [5][6] - The net loss for Q4 2025 was CAD 8.2 million or CAD 0.27 per share, compared to a net loss of CAD 4.9 million or CAD 0.20 per share in Q4 2024 [6] Business Line Data and Key Metrics Changes - Recurring revenue for Q4 2025 was $2.3 million, while one-time sales of capital equipment accounted for $3.7 million [4] - The company had 78 TULSA-PRO sites as of December 31, 2025, with a growing sales pipeline of 110 new systems in various stages of the sales process [22] Market Data and Key Metrics Changes - The company is seeing broader adoption of TULSA-PRO across both academic and community hospitals, driven by increased awareness of clinical benefits and established reimbursement pathways [22][24] - TULSA reimbursement was confirmed for 2026 at Urology level 7, with expectations for private insurance coverage decisions in the second half of 2026 [24] Company Strategy and Development Direction - The company aims to establish TULSA as a third distinct category in prostate cancer treatment, capable of treating the whole gland or specific regions while minimizing side effects [28][29] - Strategic partnerships with distributors in Saudi Arabia and Australia are expected to enhance market presence and sales [26][27] - The introduction of the TULSA-AI Volume Reduction module is anticipated to streamline BPH treatment and expand the total addressable market significantly [36][45] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitable growth, projecting a path to cash flow positivity as revenues grow and margins remain high [7][25] - The company expects to reach high double-digit to low triple-digit revenue growth in 2026, supported by new clinical data and product offerings [25][47] Other Important Information - The CAPTAIN trial, a significant clinical study, is set to present its first outcomes at the European Association of Urology meeting, which may influence reimbursement timelines [15][76] - The company is also exploring opportunities with its Sonalleve technology for treating conditions like adenomyosis and pancreatic cancer [43][44] Q&A Session Summary Question: Update on private payers and reimbursement - Management reported that the number of patients going through private payers is increasing, with typical payments between 1.5 to 2.5 times Medicare rates, and over 90% of rejections are being tracked for potential reversals [49][50] Question: Dynamics of non-capital revenue decline - Management noted that while there was a sequential decline in non-capital revenue, overall usage is increasing, and the mix is expected to shift towards recurring revenue as the install base grows [55][56] Question: Expectations for 2026 revenue growth - Management did not provide specific guidance but indicated confidence in achieving a range of 90% to 110% growth based on the number of new sites and product offerings [66][71] Question: Progress on TULSA installations - Management confirmed that installations are progressing well, with expectations for increased installations in the first quarter and throughout the year [85] Question: Use of the BPH module - At least 10 sites are currently using the BPH module, with expectations to increase to 30-40 sites by mid-year [92] Question: International expansion progress - Management highlighted growing interest in international markets and recent distributor agreements, with introductory pricing aimed at facilitating market entry [93]